MCAM upregulation in cancer cells is associated with changes in EMT marker levels, such as downregulation of the epithelial marker E-cadherin and upregulation of mesenchymal markers such as vimentin, fibronectin, β-catenin, and N-cadherin [129, 131, 134, 138]. This evidence concerns the gene MCAM and cancer.